title: [Predictive significance of serum 90K/Mac-2BP on chemotherapy response in non-Hodgkin's lymphoma].
abstract: OBJECTIVE
  For newly diagnosed non-Hodgkin's lymphoma (NHL), CHOP regimen shows good response, but quite a few patients belong to intrinsic drug resistance, or relapse after complete remission (CR). Clinical study has been focused on screening them out and improving the therapeutic response. The purpose of this study was to explore the predictive value of serum 90K/Mac-2BP on chemotherapy response in newly diagnosed NHLs, and to analyze the potential significance of serum 90K/Mac-2BP as a tumor marker in NHLs.
  
  
  METHODS
  Thirty healthy donors and 100 newly diagnosed patients were included in this study. Serum 90K/Mac-2BP level was measured with the quantitative sandwich enzyme linked immunosorbent assay (ELISA), and the relationship between serum 90K/Mac-2BP level and the therapeutic response as well as clinicopathological features was analyzed.
  
  
  RESULTS
  The level of serum 90K/Mac-2BP was associated with the response of the initial treatment in patients who received CHOP (CTX, ADM, VCR, Pred) chemotherapy. The response rate in patients with higher level (mean serum level >13.62 microg/ml) of 90K/Mac-2BP was 47.6% (20/42). The response rate in patients with lower level (mean serum level <or=13.62 microg/ml) reached 93.6% (44/47) (P< 0.001). The level of serum 90K/Mac-2BP was not relevant to age, gender, pathologic classification, performance status, Ann Arbor stage, international prognostic index(IPI),serum level of lactate dehydrogenase(LDH), bone marrow involvement, and bulky disease (P >0.05).
  
  
  CONCLUSIONS
  The level of serum 90K/Mac-2BP might predict the response of CHOP chemotherapy in NHLs, and is hopeful to be a new tumor marker.
authors.affiliation: Department of Medical Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, PR China.
authors.forename: Dong-Sheng
authors.initials: DS
authors.lastname: Zhang
authors.forename: Wen-Qi
authors.initials: WQ
authors.lastname: Jiang
authors.forename: Su
authors.initials: S
authors.lastname: Li
authors.forename: Xiao-Shi
authors.initials: XS
authors.lastname: Zhang
authors.forename: Hua
authors.initials: H
authors.lastname: Mao
authors.forename: Xiao-Qin
authors.initials: XQ
authors.lastname: Chen
authors.forename: Yu-Hong
authors.initials: YH
authors.lastname: Li
authors.forename: Jing
authors.initials: J
authors.lastname: Zhan
authors.forename: Feng-Hua
authors.initials: FH
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006023:Glycoproteins; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood*; D011239:Prednisolone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage; D016326:Extracellular Matrix Proteins
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D003520:Cyclophosphamide; D004317:Doxorubicin; D006023:Glycoproteins; D008074:Lipoproteins; D009363:Neoplasm Proteins; D011239:Prednisolone; D014750:Vincristine; C081856:LGALS3BP protein, human; D016326:Extracellular Matrix Proteins